Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018)

Objectives: This study presents 2016-2018 in vitro antimicrobial activity data and rates of resistant phenotypes for clinical isolates of Acinetobacter baumannii from Africa/Middle East, Asia/South Pacific, Europe, Latin America, and North America. Methods: A total of 4320 A. baumannii isolates were collected across all regions between 2016 and 2018. The in vitro antimicrobial activities of amikacin, colistin, levofloxacin, meropenem, and tigecycline were determined using the broth microdilution methodology of the Clinical and Laboratory Standards Institute. MICs were interpreted using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (version 11.0). Rates of subsets that were resistant to amikacin, colistin, levofloxacin, and meropenem, according to EUCAST breakpoints, are also presented. Results: In each region, tigecycline and colistin were active against isolates of A. baumannii (MIC 90 values, 1 or 2 mg/L) and the lowest rate of resistance was to colistin (1.2%-7.3%). The rates of resistance to the panel of agents were generally lower among A. baumannii from North America (1.3%-42.7%), compared with the other regions. Fewer than 11% of meropenem-resistant A. baumannii were also resistant to colistin. The rates of amikacin-, levofloxacin- and meropenem-resistant A. baumannii were lowest in North America and mostly higher in Africa/Middle East and Latin America. Conclusion: In each geographical region, tigecycline and colistin maintained good in vitro antimicrobial activity against isolates of A. baumannii , including antimicrobial-resistant subsets. The higher rates of meropenem-resistant isolates, particularly in Africa/Middle East and Latin America, require continued monitoring because of the scarcity of effective treatment options. (c) 2022 The Pfizer Inc and The Author(s). Published by Elsevier Ltd. On behalf of International Society ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Automated summary

This study investigated the in vitro antimicrobial activity and rates of resistance of Acinetobacter baumannii isolates from different regions between 2016 and 2018. Tigecycline and colistin exhibited good antimicrobial activity against the isolates, with lower resistance rates in North America. The higher rates of meropenem-resistant isolates in Africa/Middle East and Latin America require continued monitoring.